High-altitude exposure, characterized by hypobaric hypoxia, cold, and intense radiation, profoundly remodels the gut microbiota, triggering a cascade of physiological and pathological changes that extend far beyond the gastrointestinal tract. As millions travel to or reside in regions above 2500 meters, understanding this gut-centric axis has become critical for managing health risks. Hypoxia disrupts the delicate balance of the gut ecosystem, leading to dysbiosis, impaired barrier function, and increased intestinal permeability. This allows bacterial translocation and systemic inflammation, which underpin conditions like acute and chronic mountain sickness. Crucially, the gut microbiome acts as a dynamic environmental sensor; its altered production of metabolites—particularly short-chain fatty acids (SCFAs) and bile acids—directly influences host energy metabolism, immune responses, and acclimatization capacity. These changes are increasingly implicated in a spectrum of diseases, from metabolic disorders to colorectal cancer, positioning the gut as a central mediator of high-altitude health. This review synthesizes evidence from human and animal studies to elucidate how high-altitude stress reshapes the microbial landscape, explores the mechanisms linking microbiota to disease, and evaluates emerging microbiome-based interventions for promoting resilience.
The gut microbiota, a complex consortium of bacteria, fungi, viruses, and archaea, is highly sensitive to environmental extremes. Methodologies like 16S rRNA sequencing and shotgun metagenomics have revealed that high-altitude exposure consistently reduces microbial diversity and drives compositional shifts. Key changes include a decline in beneficial SCFA-producing genera (e.g., Faecalibacterium, Roseburia) and an expansion of opportunistic pathogens and pro-inflammatory taxa. These alterations are driven by multiple stressors: hypoxia directly suppresses the oxygen-consuming β-oxidation of butyrate in colonocytes, increasing luminal oxygen and favoring aerotolerant bacteria over obligate anaerobes. Concurrently, cold stress and dietary shifts at altitude further reshape the microbial community. The functional consequences are significant; the microbiota's ability to ferment dietary fiber and produce essential metabolites is compromised, disrupting a critical communication channel between the gut and distant organs.
A primary consequence of high-altitude dysbiosis is the breakdown of the gut barrier, a multi-layered defense system comprising chemical, physical, and immune components. Under hypoxic stress, the production of mucins and antimicrobial peptides by goblet and Paneth cells is impaired. Simultaneously, dysbiosis weakens tight junctions between epithelial cells, increasing intestinal permeability. This "leaky gut" allows lipopolysaccharides (LPS) and other bacterial products to enter the circulation, triggering systemic inflammation via Toll-like receptor (TLR) and NF-κB signaling pathways. This inflammatory state is a hallmark of poor acclimatization. The microbiota's role in barrier maintenance is partly mediated by metabolites: SCFAs like butyrate serve as the primary energy source for colonocytes and promote the differentiation of regulatory T cells (Tregs), fostering immune tolerance. Bile acids, modified by gut bacteria, activate receptors such as FXR and TGR5 to regulate inflammation and glucose homeostasis. At altitude, the disruption of these microbial-metabolite axes removes a crucial layer of protection, exacerbating local and systemic vulnerability.
The impact of gut remodeling is evident in specific altitude-related illnesses. In acute mountain sickness (AMS) and its severe forms (high-altitude pulmonary and cerebral edema), studies show a correlation between dysbiosis and symptom severity. Enrichment of bacteria like Klebsiellaand Escherichiahas been linked to increased levels of pro-inflammatory metabolites, contributing to vascular leakage and edema. For chronic mountain sickness (CMS), long-term residents with excessive erythrocytosis exhibit distinct microbial signatures, suggesting the gut may influence hematological adaptation. Beyond classical altitude sickness, high-altitude microbiota changes are associated with an increased risk of metabolic diseases (obesity, diabetes), gastrointestinal disorders (IBS, colorectal cancer), and even osteoporosis. This occurs through multiple pathways: inflammation-driven insulin resistance, altered bile acid metabolism affecting lipid absorption, and microbial modulation of bone turnover. The gut-liver axis is particularly important, as dysbiosis can promote cholelithiasis (gallstones) by altering bile acid composition and cholesterol saturation.
Individual variability in acclimatization is heavily influenced by baseline microbiota and the capacity for microbial adaptation. Longitudinal studies reveal that individuals with a more resilient microbial community, often characterized by higher diversity and robust SCFA production, adapt more smoothly to altitude. Interestingly, long-term high-altitude natives exhibit microbial profiles distinct from low-altitude populations, suggesting evolutionary adaptation. For instance, natives often have enriched Prevotellaand unique microbial gene sets optimized for energy harvest from fibrous diets, which may confer a metabolic advantage. In contrast, immigrants and sojourners experience more pronounced and often detrimental shifts. Diet is a major modifier; high-carbohydrate diets can support beneficial fermentative bacteria, while high-fat diets may exacerbate dysbiosis. The concept of "enterotypes" (e.g., Bacteroides- vs. Prevotella-dominant) provides a framework for understanding how pre-existing microbial states predispose individuals to different health outcomes at altitude.
Given the central role of the microbiota, microbiome-targeted therapies represent a promising frontier for managing high-altitude illness. Probiotics and prebiotics have shown potential in animal models to restore microbial balance, strengthen the gut barrier, and reduce inflammation. More notably, fecal microbiota transplantation (FMT) has demonstrated efficacy in preclinical studies, transferring a "resilient" microbial phenotype from acclimatized donors to susceptible recipients, resulting in improved physiological performance and reduced pathology. Future therapeutic strategies may involve personalized microbial consortia or metabolites (postbiotics) designed to correct specific deficits, such as butyrate supplementation to enhance barrier function or bile acid modulators to improve metabolism. However, challenges remain in standardizing interventions and understanding the long-term consequences of artificially altering the gut ecosystem in extreme environments.
In summary, high-altitude exposure initiates a profound reprogramming of the gut microbiota, which acts as a key intermediary between environmental stress and host health. The resulting dysbiosis, barrier dysfunction, and metabolite imbalance contribute significantly to the pathogenesis of altitude sickness and related chronic diseases. Deciphering the complex interactions within the "gut-altitude axis" not only deepens our understanding of human adaptation but also opens avenues for novel diagnostics and interventions aimed at promoting safer and healthier stays at high altitude.
DOI
10.1007/s11684-026-1206-2